News Home

Is Accelerate Diagnostics Inc (AXDX) a Stock to Watch After Gaining 31.63% This Week?

Thursday, August 18, 2022 10:43 AM | InvestorsObserver Analysts

Mentioned in this article

Is Accelerate Diagnostics Inc (AXDX) a Stock to Watch After Gaining 31.63% This Week?

Accelerate Diagnostics Inc (AXDX) stock has risen 31.63% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Accelerate Diagnostics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AXDX!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With AXDX Stock Today?

Accelerate Diagnostics Inc (AXDX) stock is trading at $2.83 as of 10:29 AM on Thursday, Aug 18, a decline of -$0.59, or -17.25% from the previous closing price of $3.42. The stock has traded between $2.41 and $2.96 so far today. Volume today is above average. So far 705,661 shares have traded compared to average volume of 508,120 shares.

More About Accelerate Diagnostics Inc

Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. Click Here to get the full Stock Report for Accelerate Diagnostics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App